Is it safe?
Can REGN take a bad year?
Regeneron Pharmaceuticals holds $6.01B more cash than debt, so a bad year is a question about profits, not about lenders.
$6.01B
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 6.47
Altman Z-score · safe zone, above 3
- Interest cover
- 69.4×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $1.99B
- Cash and short-term investments
- $7.99B
- Net cash
- $6.01B
- EBITDA, trailing twelve months
- $4.37B
- Operating profit, trailing twelve months
- $3.84B
- Debt / equity
- 0.06×
- Total debt / EBITDA
- 0.45×
- Annualised volatilitytwo years of daily moves
- 37%
- Worst drawdown on file
- −60%
- Below its 52-week high
- −3.1%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.